ArticleJournal of virology2019
Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial.
Open access · bronzeAbstract read
In one paragraph
Article in Journal of virology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 30 citations in OpenAlex.
- Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk.The Journal of clinical investigation · 2019Trial
- Fc effector functions in RNA viral infections: mechanisms of antiviral immunity and implications for vaccine design.Frontiers in immunology · 2026Review
- Current Approaches for Assessments of Neutralizing, Binding, and Effector Functions of Antibodies on the Path to Antibody-Mediated Prevention Strategies for HIV-1.Current HIV research · 2026Review
- Distinguishing active HIV-1 infection from vaccine-induced seropositivity in HIV vaccine trial participants.Science advances · 2025Article
- IgG and Fc Receptor Genetic Variation Associates With Functional Antibody Responses in a DNA and Protein Candidate HIV Vaccine Trial.Journal of acquired immune deficiency syndromes (1999) · 2025Article
- Article
- Potent broadly neutralizing antibodies mediate efficient antibody-dependent phagocytosis of HIV-infected cells.PLoS pathogens · 2024Article
- Vaccinomics: Paving the Way for Personalized Immunization.Current pharmaceutical design · 2024Review
- Review
- Defining genetic diversity of rhesus macaque Fcγ receptors with long-read RNA sequencing.Frontiers in immunology · 2023Article
- Transcriptome-based analysis of human peripheral blood reveals regulators of immune response in different viral infections.Frontiers in immunology · 2023Article
- Fc receptors and the diversity of antibody responses to HIV infection and vaccination.Genes and immunity · 2022Review
- Article
- FCGR3A gene duplication, FcγRIIb-232TT and FcγRIIIb-HNA1a associate with an increased risk of vertical acquisition of HIV-1.PloS one · 2022Article
- Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection.Human vaccines & immunotherapeutics · 2021Review
- Current approaches to HIV vaccine development: a narrative review.Journal of the International AIDS Society · 2021Review
- Dendritic Cell Tumor Vaccination via Fc Gamma Receptor Targeting: Lessons Learned from Pre-Clinical and Translational Studies.Vaccines · 2021Review
- FcγR Genetic Variation and HIV-1 Vaccine Efficacy: Context And Considerations.Frontiers in immunology · 2021Article
- An HIV Vaccine Protective Allele inFrontiers in immunology · 2021Article
- Immunoprofiling Correlates of Protection Against SHIV Infection in Adjuvanted HIV-1 Pox-Protein Vaccinated Rhesus Macaques.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 11 institutions in 1 country.
Shuying S LiVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Peter B GilbertVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Lindsay N CarppVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.ORCID 0000-0003-0333-5925
Chul-Woo PyoClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Holly JanesVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Youyi FongVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Xiaoying ShenDuke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.ORCID 0000-0002-8387-3952
Scott D NeidichDuke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
Derrick GoodmanDuke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
Allan deCampVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Kristen W CohenVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Guido FerrariDuke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
Scott M HammerDivision of Infectious Diseases, Columbia University College of Physicians and Surgeons, New York, New York, USA.
Magdalena E SobieszczykDivision of Infectious Diseases, Columbia University College of Physicians and Surgeons, New York, New York, USA.
Mark J MulliganDepartment of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Susan P BuchbinderDepartment of Medicine, University of California, San Francisco, California, USA.
Michael C KeeferDivision of Infectious Diseases, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Edwin DeJesusOrlando Immunology Center, Orlando, Florida, USA.
Richard M NovakUniversity of Illinois at Chicago, Chicago, Illinois, USA.
Ian FrankDivision of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
M Juliana McElrathVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Georgia D TomarasDuke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
Daniel E GeraghtyClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA geraghty@fredhutch.org xpeng5@ncsu.edu.
Xinxia PengDepartment of Molecular Biomedical Sciences, North Carolina State University, Raleigh, North Carolina, USA geraghty@fredhutch.org xpeng5@ncsu.edu.ORCID 0000-0002-0117-3582
Fred Hutch Cancer Center · USDuke University · USColumbia University · USUniversity of Washington · USEmory University · USNorth Carolina State University · USOrlando Immunology Center · USUniversity of California, San Francisco · USUniversity of Illinois Chicago · USUniversity of Pennsylvania · USUniversity of Rochester · US
Funding
LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6MLC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6MSDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9MVirus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI DAVID S METZGER · 1999 to 2026
$78.6MSocial and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI GEORGIA Doris TOMARAS · 2005 to 2026
$50.5MUniversity of Pennsylvania HIV Clinical Trials UnitUM1AI069534 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Ian Frank, PABLO TEBAS · 2012 to 2026
$33.0MUniversity of Rochester HIV/AIDS Clinical Trials Unit Administrative SupplementUM1AI069511 · NIAID · UNIVERSITY OF ROCHESTER · PI Paul R Bohjanen, MICHAEL C KEEFER · 2012 to 2026
$25.7MPhysical Resources CoreP01AI120756 · NIAID · DUKE UNIVERSITY · PI TOMARAS, GEORGIA DORIS · 2016 to 2020
$17.1MALABAMA/ZAMBIA HIV VACCINE CLINICAL TRIALS UNIT (HVTU)U01AI047996 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GOEPFERT, PAUL A. · 2000 to 2006
$8.4MStatistical methods for HIV-1 immune correlates studiesR01AI122991 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI FONG, YOUYI · 2016 to 2020
$1.6MImpact of Gastrointestinal Microbiome on the Host Response to an Effector-Memory T-Cell AIDS Vaccine and Multiple Low-Dose ChallengeR21AI120713 · NIAID · UNIVERSITY OF WASHINGTON · PI PENG, XINXIA · 2015 to 2016
$445kIdentifying cellular long non-coding RNAs as targets for HIV interventionR21AI125040 · NIAID · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI PENG, XINXIA · 2016 to 2017
$431kNIAID NIH HHS P01 AI120756NIAID NIH HHS P30 AI045008NIAID NIH HHS P30 AI064518NIAID NIH HHS R01 AI122991NIAID NIH HHS R21 AI120713NIAID NIH HHS R21 AI125040NIAID NIH HHS U01 AI047996NIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI068618NIAID NIH HHS UM1 AI068635NIAID NIH HHS UM1 AI069511NIAID NIH HHS UM1 AI069534NIMH NIH HHS R21 MH083308
Abstract
HIV Vaccine Trials Network (HVTN) 505 was a phase 2b efficacy trial of a DNA/recombinant adenovirus 5 (rAd5) HIV vaccine regimen. Although the trial was stopped early for lack of overall efficacy, later correlates of risk and sieve analyses generated the hypothesis that the DNA/rAd5 vaccine regimen protected some vaccinees from HIV infection yet enhanced HIV infection risk for others. Here, we assessed whether and how host Fc gamma receptor (FcγR) genetic variations influenced the DNA/rAd5 vaccine regimen's effect on HIV infection risk. We found that vaccine receipt significantly increased HIV acquisition compared with placebo receipt among participants carrying the FCGR2C-TATA haplotype (comprising minor alleles of four
Indexed as
Polymorphism, Single NucleotideAntibodies, MonoclonalB-LymphocytesCase-Control StudiesCD8-Positive T-LymphocytesClinical Trials, Phase II as Topicenv Gene Products, Human Immunodeficiency VirusGenetic VectorsHIV-1HIV InfectionsHIV SeropositivityHumansIncidencePhagocytosisReceptors, IgGUnited StatesAntibodies, Monoclonalenv Gene Products, Human Immunodeficiency VirusFCGR2A protein, humanFCGR2B protein, humangp140 envelope protein, Human immunodeficiency virus 1Receptors, IgGVaccines, DNAFc gamma receptorgenetic polymorphismsHIV/AIDS vaccine trialHVTN 505
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.